The legislative effort is an attempt to fight the nearly 300 percent increase in the cost of the life saving drug, according to the report.
“I believe there should be transparency across the health care system,” Sen. Yvanna Cancela, D-Nev., who sponsored the bill, told Kaiser Health News.
Nevada would be the first state to track insulin manufacturer profits, as bills addressing the escalating drug costs in other states have stalled.
More articles on supply chain:
AstraZeneca divests migraine drug for $302M
Advocacy group calls for FDA action on Bayer’s birth control device
Walmart pledges to slash supply chain greenhouse gas emission by 1B tons
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
